Novel Therapeutic Approaches to Treat Alzheimer's Disease and Memory Disorders
- *Corresponding Author:
- Dr. Michael W. Parker
Biota Structural Biology Laboratory
St. Vincent’s Institute of Medical Research
9 Princes Street, Fitzroy, Victoria 3065, Australia
Tel : 0061 3 9288 2480
Fax : 0061 3 9416 2676
E-mai : [email protected]
Received Date: August 09, 2008; Accepted Date: October 14, 2008; Published Date: December 05, 2008
Citation: David BA, Gabriela ANC, Hooi LN, Craig JM, Michael WP, et al. (2008) Novel Therapeutic Approaches to Treat Alzheimer’s Disease and Memory Disorders. J Proteomics Bioinform 1: 464-476. doi: 10.4172/jpb.1000054
Copyright: © 2008 David BA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cognitive decline most commonly associated with Alzheimer’s dementia can also result from other conditions including cerebral ischemia or brain trauma. One quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment underscoring the need for effective classes of cognitive-enhancing agents. In this mini-review we highlight recent work from our laboratory on the structural biology of Alzheimers disease and other memory disorders that was presented at the recent PRICPS – AOHUPO 2008 Conference held in Cairns, Australia. Our current work is focused on two proteins, amyloid precursor protein and insulin-regulated aminopeptidase, that are promising targets for the development of anti-Alzheimer’s drugs and as cognitive enhancers. In both cases structures determined by X-ray crystallography are being used to discover promising lead compounds by structure-based drug design.